TrialThe Journal of urology2022

Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.

Alexander Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.